304 related articles for article (PubMed ID: 22136068)
21. Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Calmy A; Vallier N; Nguyen A; Lange JM; Battegay M; de Wolf F; Reiss P; Lima VD; Hirschel B; Hogg RS; Yip B; Montaner JS; Wit FW; ; ;
Antivir Ther; 2009; 14(7):931-8. PubMed ID: 19918097
[TBL] [Abstract][Full Text] [Related]
22. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
23. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Smith DE; Chan DJ; Maruszak H; Jeganathan S
Int J STD AIDS; 2011 Apr; 22(4):228-30. PubMed ID: 21515757
[TBL] [Abstract][Full Text] [Related]
25. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Moodley D; Moodley J; Coovadia H; Gray G; McIntyre J; Hofmyer J; Nikodem C; Hall D; Gigliotti M; Robinson P; Boshoff L; Sullivan JL;
J Infect Dis; 2003 Mar; 187(5):725-35. PubMed ID: 12599045
[TBL] [Abstract][Full Text] [Related]
26. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
27. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
[TBL] [Abstract][Full Text] [Related]
28. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
29. Once-daily dosing of nevirapine in HAART.
Clotet B
J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
[TBL] [Abstract][Full Text] [Related]
30. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
31. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
[TBL] [Abstract][Full Text] [Related]
33. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
[TBL] [Abstract][Full Text] [Related]
35. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.
Ena J; Leach A; Nguyen P
HIV Med; 2008 Oct; 9(9):747-56. PubMed ID: 18651856
[TBL] [Abstract][Full Text] [Related]
36. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
[TBL] [Abstract][Full Text] [Related]
37. A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.
Zijenah LS; Kadzirange G; Rusakaniko S; Kufa T; Gonah N; Tobaiwa O; Gwanzura C; Matsikire E; Katzenstein DA
Cent Afr J Med; 2006; 52(1-2):1-8. PubMed ID: 17892232
[TBL] [Abstract][Full Text] [Related]
38. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
[TBL] [Abstract][Full Text] [Related]
39. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.
Maitland D; Jackson A; Osorio J; Mandalia S; Gazzard BG; Moyle GJ;
HIV Med; 2008 Oct; 9(8):667-72. PubMed ID: 18631255
[TBL] [Abstract][Full Text] [Related]
40. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]